Renal & Urology

Urinary Incontinence

Urinary incontinence is involuntary urine leakage; the pattern—effort-related, urgency-related, mixed, continuous or dribbling from retention—identifies the mechanism and determines whether pelvic-floor training, bladder training, medicines, catheterisation or specialist treatment is appropriate.

In a nutshell

Classify leakage as stress, urgency, mixed, overflow or continuous. Use a three-day bladder diary, urinalysis and selective residual measurement. Treat stress or mixed incontinence first with supervised pelvic floor muscle training for at least 3 months; treat urgency or mixed incontinence first with bladder training for at least 6 weeks, then use antimuscarinic or NICE-approved beta-3 therapy when appropriate. Never treat suspected overflow with antimuscarinics before assessing retention.

Classic presentation

Small leaks with coughing or exercise suggest stress incontinence; a sudden compelling urge followed by leakage, frequency and nocturia suggest urgency incontinence. A weak stream, palpable bladder and continuous dribble suggest overflow.

Key points

Stress leakage is synchronous with effort; urgency leakage follows a compelling urge; mixed symptoms contain both.
First-line stress/mixed treatment is supervised pelvic floor muscle training for at least 3 months.
First-line urgency/mixed treatment is bladder training for at least 6 weeks.
Use antimuscarinics after behavioural treatment when suitable; vibegron or mirabegron are options when antimuscarinics are unsuitable, ineffective or poorly tolerated.
Avoid immediate-release oxybutynin in older women at higher risk of sudden physical or mental deterioration, and review long-term medication.
A palpable bladder, continuous dribbling or high residual suggests overflow; treat emptying/outlet problems rather than adding an antimuscarinic.
Visible haematuria, neurological red flags, fistula symptoms and mesh complications need separate specialist pathways.

First-line investigation

Three-day bladder diary, urinalysis and focused abdominal/pelvic/neurological examination; add post-void residual when retention risk or voiding symptoms are present.

Management

Exclude retention, infection and red flags

Check urinalysis, bladder emptying and red flags before prescribing; visible haematuria, neurological change, a palpable bladder or continuous leakage needs a different pathway.^1,4,2

Classify the pattern with a bladder diary

Use a three-day frequency-volume chart and focused examination to distinguish stress, urgency, mixed, overflow and functional contributions; do not order routine imaging or urodynamics for uncomplicated initial assessment.^1,2

Use supervised behavioural treatment

Offer supervised pelvic-floor training for at least 3 months for stress/mixed incontinence and bladder training for at least 6 weeks for urgency/mixed incontinence, alongside caffeine, weight, fluid, constipation and menopause-related advice where relevant.^1,7,8

Add medication only after mechanism and residual are clear

Use an appropriate antimuscarinic for persistent overactive bladder, or NICE-approved mirabegron/vibegron when antimuscarinics are unsuitable, ineffective or poorly tolerated; avoid cognitively risky oxybutynin in vulnerable older women and review treatment regularly.^1,9,5,6

Refer refractory, male, retention and complication cases

Refer for specialist assessment when conservative treatment fails, when male/post-prostatectomy or overflow incontinence is present, or when prolapse, fistula, neurological disease or mesh complications are suspected; invasive treatment follows shared decision making and selected urodynamics.^1,2,3

Exam traps

Stress and urgency are different mechanisms: strengthen the outlet for stress and retrain/calm the detrusor for urgency.
Do not give antimuscarinics for suspected overflow before checking post-void residual.
A normal urine dipstick does not explain visible haematuria; use the suspected-cancer pathway.
Mirabegron and vibegron are not automatic first-line replacements for behavioural treatment; NICE positions them after antimuscarinics are unsuitable, ineffective or poorly tolerated.
Avoid immediate-release oxybutynin in vulnerable older women because of cognitive and physical deterioration risk.
Persistent leakage after prostate surgery, neurological signs or mesh complications require specialist pathways rather than the routine female algorithm.

Illustrations

Urodynamic pressure-flow testingRepresentative urodynamic traces plotting abdominal, vesical and calculated detrusor pressure alongside urinary flow and volume, measurements used to distinguish mechanisms contributing to urinary incontinence and voiding dysfunction.Peng S et al., Journal of Clinical Medicine 2026, CC-BY-4.0 · CC-BY-4.0

Key sources

This page is exam revision material, not medical advice, and must not be used for patient care. Always check drug doses against the BNF and current guidance. Full disclaimer.